Objective While guidelines advocate renin-angiotensin system inhibitors (RASi) for renoprotection in lupus nephritis (LN), ...

Objective Hydroxychloroquine (HCQ) is a cornerstone therapy for SLE, reducing flares, organ damage and mortality. However, ...

Objective SLE is a heterogeneous systemic autoimmune disease with diverse clinical manifestations. We aimed to identify ...

For more than a century, certain bacterial infections that breach skin or mucosal barriers have been known to act as triggers of autoimmune syndromes, including rheumatic fever and post-streptococcal ...

Background Although an early decrease in proteinuria has been correlated with good long-term renal outcome in lupus nephritis (LN), studies aimed at defining a cut-off proteinuria value are missing, ...

Objective Corticosteroids are a mainstay of SLE treatment; however, cumulative steroid exposure may lead to organ damage. This study aimed to quantify the risk of new diabetes, hypertension, cataracts ...

Objective To assess the economic burden of patients with SLE by disease severity in the USA 1 year before and after diagnosis. Methods Patients aged ≥18 years with a first SLE diagnosis (index date) ...

Objectives To achieve consensus on domains of active disease for inclusion in a novel outcome measure for SLE randomised controlled trials (RCTs), the Treatment Response Measure for SLE (TRM-SLE).

Objective Neuropsychiatric complications of systemic lupus erythematosus (SLE) lack relevant biological indicators that can be dynamically monitored. This study aims to break the technical barriers of ...

Introduction SLE is a chronic autoimmune disease characterised by multisystem involvement and fluctuating clinical course, often leading to permanent organ damage. Childhood-onset SLE (cSLE) tends to ...

Objective Strategies to Embrace Living with Lupus Fearlessly (SELF) is an online self-management education programme for people with SLE. This mixed-methods study examines SELF’s impact on ...

Objective This study examined the prevalence of major adverse cardiovascular events (MACE) among Saudi patients with SLE and the general population and considered factors associated with such outcomes ...